Auris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
03 août 2017 08h00 HE
|
Auris Medical AG
Zug, Switzerland, August 3, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Completes Acquisition of AM-125 Assets
20 juil. 2017 08h00 HE
|
Auris Medical AG
Closing of asset transfer from Otifex Therapeutics Rights to additional preclinical and clinical data complement scope of data package Initiation of Phase 1 trial of AM-125 planned for the...
Auris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
05 juil. 2017 08h00 HE
|
Auris Medical AG
Top-line results from the HEALOS trial are expected in the fall of 2017 Zug, Switzerland, July 5, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to...
Auris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris
22 juin 2017 08h00 HE
|
Auris Medical AG
Zug, Switzerland, June 22, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City
31 mai 2017 08h00 HE
|
Auris Medical AG
Program to highlight AM-125 for vertigo and upcoming Phase 3 data readouts for AM-111 and Keyzilen® Featured presentation by Dr. Elias Michaelides, Yale School of Medicine Zug, Switzerland,...
Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
11 mai 2017 06h15 HE
|
Auris Medical AG
Progressing toward completed enrollment of the AM-111 Phase 3 HEALOS trial Key Opinion Leader event scheduled for June 16 in New York City Conference call set for 8 am ET (2 pm CET) today ...
Auris Medical Reports Key Results from Keyzilen® AMPACT1 Open-Label Extension Study
09 mai 2017 08h00 HE
|
Auris Medical AG
Trial outcomes provide further evidence for safety of Keyzilen® in chronic intermittent use Exploratory efficacy results suggest potential benefits of repeating treatment cycles Zug,...
Auris Medical to Announce First Quarter 2017 Financial Results and Host Conference Call on May 11, 2017
04 mai 2017 08h00 HE
|
Auris Medical AG
Zug, Switzerland, May 4, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology,...
Auris Medical Reports Key Results from Keyzilen® AMPACT2 Open-Label Extension Study
24 avr. 2017 08h00 HE
|
Auris Medical AG
Trial outcomes show positive safety profile of Keyzilen® for chronic intermittent use Exploratory efficacy results support therapeutic concept of early tinnitus treatment Zug, Switzerland,...
Auris Medical Announces Receipt of Nasdaq Notice of Bid Price Deficiency
31 mars 2017 16h05 HE
|
Auris Medical AG
ZUG, Switzerland, March 31, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...